Bifidobacterium Probiotic Market (2033): Strain-Specific Clinical Trials, Infant Gut Microbiome Research, Wecare Probiotics and Targeted Nutrition

The Bifidobacterium Probiotic Market was valued at US$ 3.48 billion in 2025 and is projected to reach US$ 4.56 billion by 2033, growing at a CAGR of 9.6% during 2026-2033.

DataM Intelligence has released its latest "Bifidobacterium Probiotic Market Size 2026" report, delivering insights into market trends, growth opportunities, competitive dynamics, and regional performance. The report covers market size, CAGR forecasts, and emerging opportunities across food and beverages, dietary supplements, pharmaceuticals, and animal nutrition. It also examines how strain-specific clinical research, infant microbiome studies, and advances in probiotic formulation are influencing product development and commercialization strategies.

Download Sample Report (Get Higher Priority for Corporate Email ID):--
https://www.datamintelligence.com/download-sample/bifidobacterium-probiotic-market?sindhuri

United States: Recent Industry Developments
✅ August 2026: U.S. Clinical Trial Demonstrates Sustained Bifidobacterium Colonization in Infants and Toddlers - A study published in Pediatric Research on August 12, 2026, reported results from the ARTEMIS trial, a randomized, placebo-controlled study involving 114 infants and toddlers. The researchers evaluated a synbiotic formulation combining four Bifidobacterium strains with four human milk oligosaccharides (HMOs) and vitamin D. After four weeks, at least one administered bacterial strain was detected in 72% of infants and 67% of toddlers receiving the formulation. The findings highlight the potential of combining specific probiotic strains with prebiotic ingredients to support sustained gut colonization.

✅ January 2026: Wecare Probiotics Publishes Clinical Safety Findings for Bifidobacterium bifidum BBi32 - Researchers affiliated with Wecare Probiotics and Henan University of Technology published a randomized, double-blind, placebo-controlled study evaluating BBi32 in 40 participants over eight weeks. The study reported that the strain was well tolerated and found no acquired antimicrobial-resistance or virulence genes in its genome analysis. Researchers also observed improvements in gastrointestinal symptom scores and changes in selected biomarkers compared with placebo. The findings illustrate how probiotic developers are combining genomic screening, laboratory testing, and human trials to build strain-specific safety and efficacy evidence.

Find the right strategic partners to accelerate your business. Get started today:-
https://www.datamintelligence.com/partner-identification-enquiry/bifidobacterium-probiotic-market?sindhuri

Persephone Biosciences Reports Commercial Progress with Infant and Toddler Synbiotics
• Persephone Biosciences + ARTEMIS Clinical Trial: In September 2026, Persephone Biosciences marked the first anniversary of its Bloom and Thrive synbiotic products for babies and toddlers, reporting more than 1.5 million doses manufactured since launch. The company also reported clinical data from its ARTEMIS trial showing safety and tolerability, sustained Bifidobacterium colonization and measurable changes in the gut microbiome.
• Clinical Focus: The products were developed to help restore beneficial bacteria associated with early-life microbiome development. The findings add to research examining how probiotic and prebiotic combinations may influence the establishment of gut bacteria during infancy and early childhood.
• Market Significance: The development illustrates a move toward age-specific microbiome products supported by clinical evidence, rather than relying solely on broad digestive-health claims.

Top List of Key Players:
Danone S.A., International Flavors & Fragrances Inc. (IFF), Novonesis A/S, Nestlé S.A., BioGaia AB, Probi AB, Yakult Honsha Co., Ltd., Morinaga Milk Industry Co., Ltd., Lallemand Inc., Kerry Group plc, ADM, DSM-Firmenich AG, Chr. Hansen Holding A/S, Seed Health, Inc. and Persephone Biosciences, Inc.

Key Industry Developments 2026:
✅ October 2026: Japanese Researchers Register a Bifidobacterium Study Targeting Cognitive Function - A randomized, double-blind, placebo-controlled study registered in Japan on October 13 is evaluating Bifidobacterium animalis subsp. lactis LKM512 combined with arginine. Participants are scheduled to consume a daily 3 g powdered food containing at least one billion colony-forming units of the probiotic and 600 mg of arginine for 16 weeks. Researchers will assess cognitive function alongside gut microbiome composition and metabolites, extending strain-specific probiotic research into the gut-brain connection.

✅ September 2026: Persephone Biosciences Reports More Than 1.5 Million Doses of Bloom and Thrive Manufactured - The company marked one year since launching its infant and toddler synbiotic products in the United States. It also reported ARTEMIS clinical-trial findings indicating sustained Bifidobacterium colonization and measurable microbiome changes, highlighting the commercial potential of products designed around early-life gut health.

✅ August 2026: Japan Registers a Long-Term Safety Study of Bifidobacterium Foods - A clinical study registered on August 25 is evaluating the safety of consuming Bifidobacterium-containing food daily for 12 weeks in healthy adults aged 18 to under 65. Researchers will monitor blood and urine test results, vital signs, body measurements and adverse events. The study reflects the importance of documenting tolerability over sustained use, not just demonstrating short-term microbiome changes.

✅ August 2026: Japanese Researchers Register an Excess-Intake Safety Trial - A second study registered on August 25 will assess the safety of consuming Bifidobacterium-containing food at five times the recommended daily intake for four weeks. The researchers plan to monitor clinical laboratory results, blood pressure, pulse, body weight and adverse events. This work addresses a practical issue for probiotic manufacturers: establishing safety evidence for consumption levels above normal recommended use.

✅ June 2026: Clinical Trial Begins Evaluating Probiotics for Preterm Infant Neurodevelopment - A randomized controlled trial registered on ClinicalTrials.gov is investigating a probiotic combination containing Bifidobacterium animalis subsp. lactis BB-12 and Lacticaseibacillus rhamnosus GG in preterm infants. With an estimated enrolment of 116 participants, the study is designed to examine whether modifying the gut microbiota through probiotic supplementation can help protect early neurodevelopment. The trial is expected to run through December 2027, so clinical benefits have not yet been established.

✅ April 2026: Japanese Researchers Register a Study Linking Bifidobacterium, Diet and Cognitive Ageing - A population-based study registered in Japan is examining relationships between dietary patterns, gut microbiota and cognitive function in local residents. The research explores whether gut microbial composition, including Bifidobacterium levels, is associated with age-related cognitive changes. While this is observational research rather than proof that probiotics prevent cognitive decline, it highlights a new area for strain-specific product research.

✅ March 2026: Japan Registers a Randomized Trial on Bifidobacterium and Intestinal Health - A randomized, double-blind, placebo-controlled study registered on March 19 is assessing whether four weeks of Bifidobacterium-containing food improves the intestinal environment in healthy adults aged 20-64. Researchers are measuring faecal organic acids, including acetic, propionic and butyric acids, alongside microbiome composition and bowel-related outcomes. These measurements can help researchers examine biological changes beyond self-reported digestive comfort.

How Our Market Research Process Works 2026-2033:
The Bifidobacterium Probiotic Market report by DataM Intelligence draws on primary and secondary research to examine developments in probiotic strains, functional foods, dietary supplements, infant nutrition, and microbiome-based health products. It covers product launches, research collaborations, clinical trial findings, regulatory developments, and advances in probiotic formulation. The report also examines practical challenges such as strain-specific clinical evidence, bacterial survival during storage, formulation stability, and the need to demonstrate benefits for clearly defined consumer groups.

Latest M&A / Partnerships and Industry Developments in 2026:
August 2026: Persephone Biosciences Publishes Clinical Evidence for Its Bifidobacterium-Based Infant Synbiotic - Results from the ARTEMIS clinical trial were published in Pediatric Research, evaluating a synbiotic formulation containing four Bifidobacterium strains, human milk oligosaccharides (HMOs), and vitamin D3. The randomised, double-blind, placebo-controlled study enrolled 114 infants and toddlers in the United States. The researchers assessed safety, tolerability, gastrointestinal outcomes, and the ability of the supplemented bacteria to establish themselves in the gut. The findings provide clinical evidence for a formulation combining beneficial bacteria with prebiotic ingredients, rather than relying on probiotic supplementation alone.

June 2026: Australia Registers a Multi-Strain Probiotic Product Containing Bifidobacterium - Australia's Therapeutic Goods Administration listed Broad Spectrum Probiotic Triple, sponsored by Evolution Health, on June 23, 2026. Its registered ingredients include Bifidobacterium animalis subsp. lactis, Bifidobacterium infantis, Bifidobacterium lactis, and Bifidobacterium longum, alongside several Lactobacillus species. The listing illustrates the continued commercial presence of multi-strain formulations that combine different probiotic organisms in a single product. The registration is a regulatory milestone; it should not be interpreted as proof that every included strain has demonstrated the same clinical benefits.

May 2026: Yakult Reports Promising Results for Early Bifidobacterium Supplementation in Caesarean-Born Infants - Yakult published research findings on the early administration of its Bifidobacterium breve Yakult strain to infants born by planned caesarean section. The study examined the development of the intestinal microbiota, the gut environment, and growth-related indicators following supplementation beginning shortly after birth. The research addresses a specific question in infant nutrition: whether early probiotic exposure can influence gut microbiota development in infants whose initial microbial exposure may differ from that of vaginally delivered babies. The results are promising research findings, not a blanket recommendation for probiotic use in all newborns.

April 2026: Yakult Increases Bifidobacterium Content in Mirumiru and Mirumiru S Drinks - Yakult announced a reformulation of its Japanese Mirumiru and Mirumiru S fermented dairy drinks, increasing the content of its proprietary Bifidobacterium BY strain to more than 20 billion bacteria per bottle. The update is a concrete example of product differentiation through a higher declared bacterial count within an established consumer product, rather than launching an entirely new probiotic brand. It also highlights the importance of strain identity and viable bacterial quantity in product positioning.

January 2026: Clinical Research Examines the Timing and Dose of Bifidobacterium infantis Supplementation - A randomised, placebo-controlled study published in mSphere examined how the dose and timing of Bifidobacterium infantis supplementation affected the gut microbiota of breastfed infants. The findings add to the evidence that probiotic outcomes depend on how a strain is administered and the conditions of the infant gut, rather than simply on the presence of a probiotic ingredient. This is relevant to manufacturers developing infant formulas and supplements, where strain selection, dosage, feeding practices, and the ability to influence the existing microbiome all need to be considered.

Buy Now & Unlock 360° Complete Market Insights:
https://www.datamintelligence.com/buy-now-page?report=bifidobacterium-probiotic-market?sindhuri

Japan: Recent Industry Developments
✅ October 2026: Morinaga Milk Invests ¥2 Billion to Expand Probiotic Production in Japan - Morinaga Milk Industry announced an investment of approximately ¥2 billion to expand production capacity for Bifidobacterium and other probiotic cultures at the Fukui Plant of Morinaga-Hokuriku Milk Industry. Construction is scheduled to begin in October 2026, with operations expected to start in January 2029. The expansion is designed to raise the group's annual production capacity to approximately 250 tonnes, around 1.3 times its current level. The additional capacity will support probiotic and postbiotic powders used in supplements and other products, as well as supply agreements with international infant-formula manufacturers.

✅ July 2026: Morinaga Milk Reports New Findings on Bifidobacterium and Inflammatory Responses - Morinaga Milk published research in iScience examining the relationship between gut bifidobacteria and immune-cell responses. The study found that healthy adults with higher levels of bifidobacteria tended to have immune cells that produced lower levels of inflammatory substances under laboratory testing. Researchers also found that exposure to components derived from bifidobacteria reduced subsequent inflammatory responses in cell-based experiments. The findings could help guide future research into strain-derived ingredients and immune health, although further studies are needed before these results can support specific product claims.

✅ June 2026: Japanese Researchers Investigate Bifidobacterium for Athletes Following High-Protein Diets - Morinaga Milk and researchers from Juntendo University investigated Bifidobacterium longum BB536 in a randomized, double-blind, placebo-controlled study involving 60 healthy male athletes. Participants consumed 70 grams of whey protein daily alongside either BB536 or a placebo for four weeks. The researchers observed a trend toward improved diarrhea-related quality-of-life scores in the BB536 group and identified changes in certain body-odor-related metabolites that appeared to depend on participants' gut microbiota profiles. The findings highlight a more targeted approach to probiotic research, although the exploratory study did not establish a significant difference between the groups for the primary gastrointestinal outcome.

✅ May 2026: Morinaga Milk and Matsumoto City Hospital Publish Infant Probiotic Research - Morinaga Milk reported findings from a joint study with Matsumoto City Hospital examining Bifidobacterium infantis M-63 in infants and toddlers during and after weaning. The randomized, double-blind, placebo-controlled study enrolled 100 children aged five months to under three years. Participants received either a daily powder containing five billion colony-forming units of M-63 or a placebo for eight weeks. The research suggested potential improvements in bowel habits and measures of the gut environment, with possible benefits for cold-like symptoms in groups at relatively higher risk of infection. Published in Pediatric Research on April 29, 2026, the study provides evidence for continued investigation of strain-specific probiotics in early-life nutrition.

Key Segmentation Plannings (2026)
By Type: Bifidobacterium animalis, Bifidobacterium longum, Bifidobacterium bifidum, Others

By Form: Dry, Liquid

By Application: Food and Beverages, Dietary Supplements, Pharmaceuticals, Animal Feed, Others

By End-User: Infants, Adults, Children, Animals

By Region: North America, Latin America, Europe, Asia-Pacific, Middle East and Africa

Growing Demand for Gut Health Products Drives Bifidobacterium Probiotic Adoption
• Gut Health Awareness: Increasing consumer awareness of digestive health, intestinal microbiome balance and the potential benefits of probiotics is supporting demand for Bifidobacterium-based products. These probiotics are increasingly incorporated into dietary supplements, functional foods, fortified beverages and specialized nutrition products.

• Product Innovation: Manufacturers are developing probiotic formulations featuring strains such as Bifidobacterium animalis, Bifidobacterium longum and Bifidobacterium bifidum. Advances in microencapsulation, freeze-drying and formulation technologies are helping improve probiotic stability, shelf life and viability in different product formats.

• Industry Implication: Growing interest in preventive nutrition and digestive wellness is creating opportunities for probiotic ingredient suppliers, food and beverage manufacturers, supplement brands and pharmaceutical companies. Product differentiation, strain-specific research, quality assurance and effective delivery systems are becoming important competitive factors.

Regulatory Standards and Scientific Research Shape the Probiotic Market
• Quality and Safety Requirements: Probiotic manufacturers must address applicable food safety, ingredient authorization, labeling and quality-control requirements across different markets. Strain identification, microbial purity, viable cell counts and stability throughout shelf life are important considerations for product development and commercialization.

• Scientific Validation: Research into the gut microbiome and strain-specific probiotic properties is encouraging manufacturers to invest in clinical studies, product validation and evidence-based formulations. Demonstrating the benefits of individual strains for specific applications can help strengthen consumer confidence and support product differentiation.

Key Market Drivers
• Growing Consumer Awareness of Gut Health - Increasing awareness of the relationship between gut microbiota, digestive health, and overall well-being is driving demand for Bifidobacterium-based probiotic products across dietary supplements, functional foods, and beverages.

• Rising Demand for Functional Foods and Dietary Supplements - Growing consumer preference for preventive healthcare and wellness-focused nutrition is encouraging manufacturers to incorporate Bifidobacterium strains into probiotic supplements, fermented dairy products, and functional beverages.

• Expanding Applications in Infant and Adult Nutrition - Increasing demand for specialized nutritional products for infants, children, and adults is supporting the use of Bifidobacterium probiotics in formulations designed to support digestive health and maintain a balanced gut microbiome.

• Advancements in Probiotic Research and Product Innovation - Ongoing research into strain-specific benefits, improved probiotic stability, and innovative delivery formats is encouraging manufacturers to develop differentiated formulations for digestive wellness, immune health, and personalized nutrition.

FAQs
Q1: What is the current market size of the Bifidobacterium Probiotic Market and its future outlook?
Ans: The global Bifidobacterium Probiotic Market was valued at US$ 3.48 billion in 2025 and is projected to reach US$ 4.56 billion by 2033, reflecting increasing demand for gut health and probiotic nutrition products.

Q2: How fast is the Bifidobacterium Probiotic Market expected to grow during the forecast period?
Ans: The market is projected to expand at a CAGR of 9.6% from 2026 to 2033, driven by rising consumer awareness of digestive health, growing demand for functional foods, and increasing adoption of probiotic supplements.

Q3: Which region leads the Bifidobacterium Probiotic Market?
Ans: Asia-Pacific accounted for the largest share of the Bifidobacterium Probiotic Market, supported by established fermented food consumption, a large consumer base, growing health awareness, and investments in probiotic research and development.

Contact Us -
Company Name: DataM Intelligence Contact
Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.